Show simple item record

dc.contributor.authorGee, Harriet Een
dc.contributor.authorCamps, Carmeen
dc.contributor.authorBuffa, Francesca Men
dc.contributor.authorPatiar, Shalinien
dc.contributor.authorWinter, Stuart Cen
dc.contributor.authorBetts, Guy N Jen
dc.contributor.authorHomer, Jarrod Jen
dc.contributor.authorCorbridge, Rogan Jen
dc.contributor.authorCox, Graham Jen
dc.contributor.authorWest, Catharine M Len
dc.contributor.authorRagoussis, Jiannisen
dc.contributor.authorHarris, Adrian Len
dc.date.accessioned2010-08-04T11:08:11Z
dc.date.available2010-08-04T11:08:11Z
dc.date.issued2010-05-01
dc.identifier.citationhsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. 2010, 116 (9):2148-58 Canceren
dc.identifier.issn0008-543X
dc.identifier.pmid20187102
dc.identifier.doi10.1002/cncr.25009
dc.identifier.urihttp://hdl.handle.net/10541/109039
dc.description.abstractBACKGROUND: Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis. METHODS: Three hypoxia-related microRNAs, hsa-miR-210, hsa-miR-21, and hsa-miR-10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99-gene hypoxia metagene, individual hypoxia-related genes such as TWIST1, and immunohistochemical expression of hypoxia-inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs. RESULTS: Only the level of hsa-miR-210 was significantly correlated with other markers of hypoxia, including the 99-gene hypoxia metagene (rho = 0.67, P < .001). We found no association between hsa-miR-210, hsa-miR-21, or hsa-miR-10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa-miR-210 were associated with locoregional disease recurrence (P = .001) and short overall survival (P = .008). hsa-miR-21 and hsa-miR-10b had no prognostic significance. CONCLUSIONS: Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia.
dc.language.isoenen
dc.subjectTumour Cell Lineen
dc.subjectHead and Neck Canceren
dc.subjectSquamous Cell Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnoxia
dc.subject.meshCell Line, Tumor
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshHead and Neck Neoplasms
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMicroRNAs
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms, Squamous Cell
dc.subject.meshPrognosis
dc.subject.meshRNA Precursors
dc.subject.meshTumor Markers, Biological
dc.titlehsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.en
dc.identifier.journalCanceren
html.description.abstractBACKGROUND: Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis. METHODS: Three hypoxia-related microRNAs, hsa-miR-210, hsa-miR-21, and hsa-miR-10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99-gene hypoxia metagene, individual hypoxia-related genes such as TWIST1, and immunohistochemical expression of hypoxia-inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs. RESULTS: Only the level of hsa-miR-210 was significantly correlated with other markers of hypoxia, including the 99-gene hypoxia metagene (rho = 0.67, P < .001). We found no association between hsa-miR-210, hsa-miR-21, or hsa-miR-10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa-miR-210 were associated with locoregional disease recurrence (P = .001) and short overall survival (P = .008). hsa-miR-21 and hsa-miR-10b had no prognostic significance. CONCLUSIONS: Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia.


This item appears in the following Collection(s)

Show simple item record